XML 67 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
INTANGIBLE ASSETS (Details ) (USD $)
3 Months Ended 12 Months Ended
Mar. 31, 2015
Dec. 31, 2014
Finite-Lived Intangible Assets    
Accumulated Amortization $ (120,331)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization $ (113,640)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Indefinite-Lived Intangible Assets    
Gross Carrying Amount 1,379,081us-gaap_IntangibleAssetsGrossExcludingGoodwill 1,342,228us-gaap_IntangibleAssetsGrossExcludingGoodwill
Net Amount 1,258,750us-gaap_IntangibleAssetsNetExcludingGoodwill 1,228,588us-gaap_IntangibleAssetsNetExcludingGoodwill
Hormone therapy drug candidate patents - Pending [Member]    
Indefinite-Lived Intangible Assets    
Gross Carrying Amount 691,465us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_HormoneTherapyDrugCandidatePatentsMember
675,982us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_HormoneTherapyDrugCandidatePatentsMember
Net Amount 691,465txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_HormoneTherapyDrugCandidatePatentsMember
675,982txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_HormoneTherapyDrugCandidatePatentsMember
Multiple trademarks for vitamins/supplements [Member]    
Indefinite-Lived Intangible Assets    
Gross Carrying Amount 124,738us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_MultipleTrademarksForVitaminsSupplementsMember
103,368us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_MultipleTrademarksForVitaminsSupplementsMember
Net Amount 124,738txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_MultipleTrademarksForVitaminsSupplementsMember
103,368txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_MultipleTrademarksForVitaminsSupplementsMember
OPERA software patent [Member]    
Finite-Lived Intangible Assets    
Gross Carrying Amount 31,951us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_ComputerSoftwareIntangibleAssetMember
31,951us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_ComputerSoftwareIntangibleAssetMember
Accumulated Amortization (2,995)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_ComputerSoftwareIntangibleAssetMember
(2,496)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_ComputerSoftwareIntangibleAssetMember
Net Amount 28,956us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_ComputerSoftwareIntangibleAssetMember
29,455us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_ComputerSoftwareIntangibleAssetMember
Weighted Average Amortization Period 14 years 6 months 14 years 9 months
Development costs for corporate website [Member]    
Finite-Lived Intangible Assets    
Gross Carrying Amount 91,743us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InternetDomainNamesMember
91,743us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InternetDomainNamesMember
Accumulated Amortization (91,743)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InternetDomainNamesMember
(91,743)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InternetDomainNamesMember
Net Amount      
Approved Hormone Therapy Drug Candidate Patents [Member]    
Finite-Lived Intangible Assets    
Gross Carrying Amount 439,184us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
439,184us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Accumulated Amortization (25,593)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
(19,401)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Net Amount $ 413,591us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
$ 419,783us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Weighted Average Amortization Period   18 years
Non-Amortizing Intangible Assets [Member]    
Finite-Lived Intangible Assets    
Weighted Average Amortization Period 17 years 9 months